FRI, FEB 21, 2020 09:05 CET
Episurf Medical (NASDAQ: EPIS B) today announces that the company has reached another milestone by the planning of the 700th surgery with the Episealer® knee implant in the coming weeks. The reported implant revision rates remain low and presented clinical data is showing significant improvements for the Episealer® patients. About 275 patients have currently had the Episealer® implant for more than two years and about 25 patients for more than five years.
“This is becoming a significant patient population and we look forward to seeing more clinical evidence from this group of patients. The use of the Episealer® is definitely increasing and in Q1 2020, we have already exceeded the average quarterly volumes from 2019, indicating that also our customers are becoming more and more comfortable with this new treatment method” says Pål Ryfors, CEO Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
